Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCL1 | Q07820 | 6/20 | 0.45 |
| ▸ | PDE4A | P27815 | 1/20 | 0.41 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.41 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.41 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.41 |
| ▸ | CNR2 | P34972 | 2/20 | 0.39 |
| ▸ | SYK | P43405 | 1/20 | 0.39 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.38 |
| ▸ | ICMT | O60725 | 1/20 | 0.37 |
| ▸ | GSK3B | P49841 | 2/20 | 0.37 |
| ▸ | QPCT | Q16769 | 2/20 | 0.37 |
| ▸ | CNR1 | P21554 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26581627 | 0.96 | MCL1 (0.48) | MCL1PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL20604843 | 0.90 | MCL1 (0.42) | MCL1CNR2SYKPTGER4ICMT | |
| SCHEMBL26581608 | 0.88 | MCL1 (0.48) | MCL1ICMTGSK3BQPCT | |
| SCHEMBL20604991 | 0.86 | MCL1 (0.45) | MCL1CNR2SYKPTGER4ICMT | |
| SCHEMBL26581592 | 0.85 | HTR1A (0.44) | MCL1PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL23809509 | 0.84 | MCL1 (0.44) | MCL1CNR2SYKPTGER4ICMT | |
| SCHEMBL23809526 | 0.83 | MCL1 (0.49) | MCL1CNR2CNR1 | |
| SCHEMBL26581589 | 0.81 | MCL1 (0.48) | MCL1PTGER4 | |
| SCHEMBL26581757 | 0.81 | MCL1 (0.46) | MCL1PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL26581338 | 0.81 | MEN1 (0.36) | PTGER4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230330099-A1 | SUBSTITUTED INDOLE MCL-1 INHIBITORS | VANDERBILT UNIVERSITY | 2023-10-19 | — | — | US | disclosed |
| US-20230330099-A1 | SUBSTITUTED INDOLE MCL-1 INHIBITORS | VANDERBILT UNIVERSITY | 2023-10-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230330099-A1 | SUBSTITUTED INDOLE MCL-1 INHIBITORS | MCL1, BCL2L1, BCL9 | MCL1 1/4885PDE4A 3812/4885PDE4B 3808/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.